Cervical Cancer News and Research RSS Feed - Cervical Cancer News and Research

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.
UTMB study reveals that only about half of teenage girls get HPV vaccine at the recommended age

UTMB study reveals that only about half of teenage girls get HPV vaccine at the recommended age

It's a virus that is responsible for almost all cases of cervical cancer but a new study by University of Texas Medical Branch at Galveston researchers indicates that only about half of the girls receive the vaccine at the recommended age to best protect themselves. [More]
WHO calls for urgent action to reduce premature deaths from noncommunicable diseases

WHO calls for urgent action to reduce premature deaths from noncommunicable diseases

Urgent government action is needed to meet global targets to reduce the burden of noncommunicable diseases (NCDs), and prevent the annual toll of 16 million people dying prematurely - before the age of 70 - from heart and lung diseases, stroke, cancer and diabetes, according to a new WHO report. [More]
Two medical organizations recommend use of HPV test for cervical cancer screening

Two medical organizations recommend use of HPV test for cervical cancer screening

Two leading medical organizations say that using a Human papillomavirus (HPV) test alone for cervical cancer screening is an effective alternative to the current recommendation for screening with either cytology (the Pap test) alone or co-testing with cytology and HPV testing. [More]
New guidance recommends use of primary HPV test for cervical cancer screening

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test. [More]
Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars. [More]
Elekta's Flexitron brachytherapy afterloading platform approved in China

Elekta's Flexitron brachytherapy afterloading platform approved in China

Elekta announces that the China Food and Drug Administration has approved Elekta's Flexitron brachytherapy afterloading platform for sale and marketing in China. [More]
UCLA researchers develop lens-free microscope that can detect cancer, other cell-level abnormalities

UCLA researchers develop lens-free microscope that can detect cancer, other cell-level abnormalities

UCLA researchers have developed a lens-free microscope that can be used to detect the presence of cancer or other cell-level abnormalities with the same accuracy as larger and more expensive optical microscopes. [More]
Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

Cervical cancer is, in many ways, a shining example of how successful the war on cancer can be. Thanks largely to the advent of Pap smear screening, U.S. cervical cancer deaths decreased dramatically, by more than 60 percent, between 1955 and 1992. In the last two decades, better treatment outcomes and more powerful imaging techniques have steadily pushed 5-year survival rates ever higher. [More]
MD Anderson president applauds FDA's approval of new vaccine for HPV-related cancers

MD Anderson president applauds FDA's approval of new vaccine for HPV-related cancers

The Food and Drug Administration's approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center. [More]
Study sheds light on common psychosocial barriers affecting HPV vaccination in Puerto Rico

Study sheds light on common psychosocial barriers affecting HPV vaccination in Puerto Rico

Young Puerto Rican women and their mothers know little about the human papillomavirus (HPV) and cervical cancer, according to researchers at The University of Texas Health Science Center at Houston School of Public Health. [More]

MRIGlobal awarded $3 million contract to provide HPV vaccine

MRIGlobal today announced that it has been awarded a $3 million contract amendment from the National Cancer Institute's PREVENT Cancer Program to provide a vaccine for the Human Papillomavirus or HPV, the most common sexually transmitted infection in the United States. MRIGlobal will lead a team that will produce the vaccine to be used in a Phase I clinical trial. [More]
New WHO guidance provides cervical cancer control and prevention approach

New WHO guidance provides cervical cancer control and prevention approach

New guidance from WHO aims to help countries better prevent and control cervical cancer. The disease is one of the world's deadliest - but most easily preventable - forms of cancer for women, responsible for more than 270 000 deaths annually, 85% of which occur in developing countries. [More]
Researchers find way to prevent noise-induced hearing loss

Researchers find way to prevent noise-induced hearing loss

Researchers from Weill Cornell Medical College and the Gladstone Institutes have found a way to prevent noise-induced hearing loss in a mouse using a simple chemical compound that is a precursor to vitamin B3. This discovery has important implications not only for preventing hearing loss, but also potentially for treating some aging-related conditions that are linked to the same protein. [More]
Study finds striking gap in cancer survival between countries and regions

Study finds striking gap in cancer survival between countries and regions

The CONCORD-2 study, published in The Lancet, reports 5-year survival estimates for 25ยท7 million cancer patients diagnosed with one of 10 common cancers and 75 000 children diagnosed with acute lymphoblastic leukaemia between 1995 and 2009, using individual patient data from 279 cancer registries in 67 countries. [More]
Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014. [More]
Eight million US women skip cervical cancer screening in the past five years

Eight million US women skip cervical cancer screening in the past five years

Despite evidence that cervical cancer screening saves lives, about eight million women ages 21 to 65 years have not been screened for cervical cancer in the past five years, according to a new Vital Signs report from the Centers for Disease Control and Prevention. More than half of new cervical cancer cases occur among women who have never or rarely been screened. [More]
Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Advaxis, Inc., a cancer immunotherapy company, today announced the abstracts of three preclinical and clinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting, November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland. [More]
Findings could lead to single blood test for early detection of many types of cancer

Findings could lead to single blood test for early detection of many types of cancer

Scientists have identified more than 800 markers in the blood of cancer patients that could help lead to a single blood test for early detection of many types of cancer in future, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Sunday). [More]
UCLA scientists find link between gigaxonin protein and HPV-positive head and neck cancers

UCLA scientists find link between gigaxonin protein and HPV-positive head and neck cancers

UCLA scientists have discovered for the first time that a protein usually linked to rare neurological disorders is also associated with human papilloma virus (HPV) positive head and neck cancers. The protein was also shown to help improve the effectiveness of chemotherapy treatments, laying the groundwork for the development of more specialized therapies. [More]
Japanese mushroom extract shows promise in eradicating HPV

Japanese mushroom extract shows promise in eradicating HPV

A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School. [More]